Semaglutide clears liver inflammation and cuts fibrosis in MASH patients, trial shows

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH). The interim results also reveal meaningful weight loss and improved cardiometabolic…

Continue ReadingSemaglutide clears liver inflammation and cuts fibrosis in MASH patients, trial shows